ID

38074

Description

Two-Part Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Pharmacodynamics of Repeat Oral Dosesof the Enteric-Coated Free Base Formulation of Darapladib (SB-480848) ina Dose Rising Fashion and to Evaluate the Safety, Tolerability and Pharmacokinetics of Darapladib when Co-administered with Ketoconazole in Healthy Adult Subjects. There are 4 parts to this study: Screening, Part A, Part B, and Follow-Up. Part A contains 2 Sessions per day for day 1-10, Part B contains 1 Session per day for day 1-14. Each itemgroup contains information when it should be filled out. The itemgroups of the non-serious and serious adverse event forms contain additional information on the definition of a serious/non-serious adverse event.

Mots-clés

Versions (1)
  1. 15/09/2019 15/09/2019 -
Détendeur de droits

GlaxoSmithKline

Téléchargé le

15 septembre 2019

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY-NC 3.0
Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Retour au modèle Commentaires
Groupe Item commentaires pour :

Item commentaires pour :

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

Darapladib Evaluation Case Report Form GSK LPL107988

Anglais

Concomitant Medication

12 Formulaires  
Administrative documentation
Description

Administrative documentation

Subject Identifier
Description

Subject Identifier

Type de données

text

Alias
UMLS CUI [1]
C2348585
Visit Date
Description

Visit Date

Type de données

date

Alias
UMLS CUI [1]
C1320303
Concomitant medications
Description

Concomitant medications

Alias
UMLS CUI-1
C2347852
Were any concomitant medications taken by the subject prior to dosing and/or during the study?
Description

If Yes, record each medication on a separate line using Trade Names where possible. If the medication is related to a Non-Serious Adverse Event or Serious Adverse Event, details should be expressed using the same terminology.

Type de données

boolean

Alias
UMLS CUI [1,1]
C2347852
UMLS CUI [1,2]
C0332152
UMLS CUI [1,3]
C0008976
UMLS CUI [2,1]
C2347852
UMLS CUI [2,2]
C0347984
UMLS CUI [2,3]
C0008976
Concomitant medications information
Description

Concomitant medications information

Alias
UMLS CUI-1
C2347852
UMLS CUI-2
C1533716
Drug Name
Description

Drug Name

Type de données

text

Alias
UMLS CUI [1,1]
C2347852
UMLS CUI [1,2]
C0027365
Unit Dose
Description

Unit Dose

Type de données

float

Alias
UMLS CUI [1]
C2826646
Units
Description

Units

Type de données

text

Alias
UMLS CUI [1]
C2826767
Frequency
Description

Frequency

Type de données

float

Alias
UMLS CUI [1]
C2826654
Route
Description

Route of administration

Type de données

text

Alias
UMLS CUI [1]
C2826730
Reason for medication
Description

Reason for medication

Type de données

text

Alias
UMLS CUI [1]
C2826696
Start Date and Time
Description

Start Date and Time

Type de données

datetime

Alias
UMLS CUI [1]
C2826734
UMLS CUI [2]
C2826740
Taken prior to study
Description

Taken prior to study

Type de données

boolean

Alias
UMLS CUI [1,1]
C2347852
UMLS CUI [1,2]
C0332152
UMLS CUI [1,3]
C0008976
Stop Date and Time
Description

Stop Date and Time

Type de données

datetime

Alias
UMLS CUI [1]
C2826744
UMLS CUI [2]
C2826659
Ongoing medication?
Description

Ongoing medication

Type de données

boolean

Alias
UMLS CUI [1]
C2826666
Retour au début de la page

Similar models

Concomitant Medication

12 Formulaires
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
Administrative documentation
Subject Identifier
Item
Subject Identifier
text
C2348585 (UMLS CUI [1])
Visit Date
Item
Visit Date
date
C1320303 (UMLS CUI [1])
Item Group
Concomitant medications
C2347852 (UMLS CUI-1)
Concomitant medications
Item
Were any concomitant medications taken by the subject prior to dosing and/or during the study?
boolean
C2347852 (UMLS CUI [1,1])
C0332152 (UMLS CUI [1,2])
C0008976 (UMLS CUI [1,3])
C2347852 (UMLS CUI [2,1])
C0347984 (UMLS CUI [2,2])
C0008976 (UMLS CUI [2,3])
Item Group
Concomitant medications information
C2347852 (UMLS CUI-1)
C1533716 (UMLS CUI-2)
Drug Name
Item
Drug Name
text
C2347852 (UMLS CUI [1,1])
C0027365 (UMLS CUI [1,2])
Unit Dose
Item
Unit Dose
float
C2826646 (UMLS CUI [1])
Units
Item
Units
text
C2826767 (UMLS CUI [1])
Frequency
Item
Frequency
float
C2826654 (UMLS CUI [1])
Route of administration
Item
Route
text
C2826730 (UMLS CUI [1])
Reason for medication
Item
Reason for medication
text
C2826696 (UMLS CUI [1])
Start Date and Time
Item
Start Date and Time
datetime
C2826734 (UMLS CUI [1])
C2826740 (UMLS CUI [2])
Taken prior to study
Item
Taken prior to study
boolean
C2347852 (UMLS CUI [1,1])
C0332152 (UMLS CUI [1,2])
C0008976 (UMLS CUI [1,3])
Stop Date and Time
Item
Stop Date and Time
datetime
C2826744 (UMLS CUI [1])
C2826659 (UMLS CUI [2])
Ongoing medication
Item
Ongoing medication?
boolean
C2826666 (UMLS CUI [1])
Retour au début de la page 

Contact

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial